Athanasoulia A P, Sievers C, Uhr M, Ising M, Stalla G K, Schneider H J
Department of Internal Medicine, Endocrinology and Clinical Chemistry, Max Planck Institute of Psychiatry, Kraepelinstrasse 2-10, 80804, Munich, Germany,
Pituitary. 2014 Jun;17(3):240-5. doi: 10.1007/s11102-013-0496-y.
Treatment with dopamine agonists in patients with prolactinomas has been associated with weight loss in short term studies. However, long-term studies on weight changes are lacking. Taq1A is a restriction fragment length polymorphism considered as a gene marker for the DRD2 gene. The presence of at least one A1 allele is linked to reduced brain dopaminergic activity due to reduced receptor binding and lower density of the dopamine 2 receptor. We aimed at testing the hypothesis that the dopaminergic treatment in prolactinoma patients leads to sustained weight loss and that the presence of diminished weight loss response under dopamine agonists is associated with the minor A1 allele of Taq1A.We included n = 44 patients (17 male and 27 female, 26 macroadenomas and 18 microadenomas) with prolactinomas treated with dopamine agonists. Outcome measures were weight and body mass index (BMI) change under dopaminergic treatment after 2 years with regard to Taq1A status and sex. We observed that the dopaminergic treatment leads to a significant mean weight loss of 3.1 ± 6.25 kg after 2 years. Regarding Taq1A polymorphisms, 21 patients were carriers of at least one A1 allele and 23 patients had a genotype of A2/A2. However, the presence of the A1 allele was neither associated with the mean BMI at baseline nor with an altered weight loss response under dopamine agonist therapy. Our results implicate that the dopaminergic treatment leads to a sustained weight loss in patients with prolactinomas after 2 years. However, there was no association to the A1 allele of Taq1A, observation that needs to be analysed in larger cohorts.
在短期研究中，用多巴胺激动剂治疗泌乳素瘤患者与体重减轻有关。然而，缺乏关于体重变化的长期研究。Taq1A是一种限制性片段长度多态性，被认为是DRD2基因的基因标记。由于受体结合减少和多巴胺2受体密度降低，至少一个A1等位基因的存在与脑多巴胺能活性降低有关。我们旨在检验以下假设：泌乳素瘤患者的多巴胺能治疗会导致体重持续减轻，并且多巴胺激动剂治疗下体重减轻反应减弱与Taq1A的次要A1等位基因有关。我们纳入了44例接受多巴胺激动剂治疗的泌乳素瘤患者（17例男性和27例女性，26例大腺瘤和18例微腺瘤）。观察指标为2年后多巴胺能治疗下与Taq1A状态和性别的体重及体重指数（BMI）变化。我们观察到，多巴胺能治疗2年后导致平均体重显著减轻3.1±6.25千克。关于Taq1A多态性，21例患者是至少一个A1等位基因的携带者，23例患者的基因型为A2/A2。然而，A1等位基因的存在既与基线时的平均BMI无关，也与多巴胺激动剂治疗下体重减轻反应的改变无关。我们的结果表明，多巴胺能治疗在2年后导致泌乳素瘤患者体重持续减轻。然而，与Taq1A的A1等位基因没有关联，这一观察结果需要在更大的队列中进行分析。
